The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

The present invention relates to a haemostatic powder comprising at least 10 wt. % of particle agglomerates, said particle agglomerates having a diameter in the range of 1-500 μm and comprising: electrophilic polyoxazoline particles containing electrophilic polyoxazoline carrying at least 3 reactive electrophilic groups that are capable of reacting with amine groups in blood under the formation of a covalent bond; and nucleophilic polymer particles containing a water-soluble nucleophilic polymer carrying at least 3 reactive nucleophilic groups that, in the presence of water, are capable of reacting with the reactive electrophilic groups of the electrophilic polyoxazoline under the formation of a covalent bond between the electrophilic polyoxazoline and the nucleophilic polymer.

When applied to a bleeding site, the haemostatic powder of the present invention turns into a gel while at the same time binding to proteins present in the blood and on the surrounding tissue.

The present invention relates to a hemostatic absorbable composition, comprising: a flowable plurality of separate aggregates each comprising: a plurality of absorbable carrier particles coated on a surface thereof by a plurality of smaller particles comprising an absorbable supplemental hemostasis-promoting agent. In some embodiments, the absorbable carrier particles comprise gelatin or collagen, and the supplemental hemostasis-promoting agent comprises oxidized cellulose, oxidized regenerated cellulose, carboxylic oxidized cellulose, carboxylic oxidized regenerated cellulose, thrombin, or tranexamic acid.

The present disclosure provides medical products including an adhesive containing a carboxyalkyl cellulose and sorbitol. Such medical products can find use as a bolster material for use in conjunction with a surgical fastening device such as a stapler. Such adhesives may include advantageous properties such as the ability to retain tack while stored under a peelable cover. Related methods of manufacture and use are also described.

The present disclosure provides a recombinant collagen and a recombinant collagen sponge material. The recombinant collagen comprises: (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2; and/or (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2. The recombinant collagen sponge material is obtained by sequential physical cross-linking and chemical cross-linking of the recombinant collagen. The recombinant collagen sponge material according to the present disclosure is capable of hemostasis, wound surface repair, moisture absorption and platelet aggregation, and has high moisture absorption, a significant hemostatic effect and good biocompatibility, assuming great clinical significance in the field of surgery.

Provided is a hemostatic dressing. The hemostatic dressing includes: a porous matrix layer including a biocompatible polymer; a hemostatic layer loaded on the porous matrix layer and including a polymer in which polyhydric phenol-containing moieties are introduced; and a binding layer interposed between the porous matrix layer and the hemostatic layer to prevent the porous matrix layer from being separated from the hemostatic layer.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

The present invention relates to a self-assembling polypeptide for use as tissue adhesive. The present invention also relates to the use of a self-assembling polypeptide as tissue adhesive. Further, the invention is directed to the use of a self-assembling polypeptide to glue one or more cosmetic compounds on skin, mucosa, and/or hair. Furthermore, the invention is directed to a self-assembling polypeptide for use in gluing one or more pharmaceutical compounds on tissue, skin, mucosa, and/or hair.

Implantable bone compositions are provided. The implantable compositions comprise hydratable bone putties. The hydratable bone putties comprise porous ceramic granules having an average diameter from about 50 μm to 800 μm. The porous ceramic granules comprise hydroxyapatite and beta-tricalcium phosphate. The implantable bone compositions further include collagen carriers. In some embodiments, the hydratable bone putty can be hydrated to form a non-settable flowable cohesive cement or gel. Methods of making and using the implantable compositions are also provided.

The present invention relates to a self-assembling polypeptide, such as a spider silk polypeptide, for use as a coating material to form a uniform coating around an implant for the purpose of reducing or preventing capsular fibrosis associated with the use of such an implant in the human body.